Journals / Ege Tıp Dergisi / 2011 / Cilt: 50 - Sayı: 4

The importance and role of anti-HCV signal/cutoff ratio in diagnosis of hepatitis C virus infection

Anti-HCV sinyal/eşik değer oranının Hepatit C virüs enfeksiyonu tanısında rolü ve önemi

Pages
223–228
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With thearchitect anti-HCV assay (Abbott, USA), in cases with signal/cutoff >3.27, the line immunoassay will be positive inmost patients, so supplementary testing in such individuals is not needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Different signal/cutoff values for different commercial kits are used to determine the samples that would predicta true antibody response for Hepatitis C Virus infection.
📊
Key Findings & Data:The aim of this study is to determine a specific signal/cutoffratio with the commercial kit that is used routinely in our laboratory that would predict a true antibody positive result95% of the time regardless of the anti-HCV prevalance.Material and Methods: A total number of 309 anti-HCV positive samples that were tested with the architect anti-HCVassay (Abbott Laboratories, IL, USA) were reviewed retrospectively and categorized according to their signal/cutoffratio.
💡
Conclusion & Impact:With thearchitect anti-HCV assay (Abbott, USA), in cases with signal/cutoff >3.27, the line immunoassay will be positive inmost patients, so supplementary testing in such individuals is not needed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Different signal/cutoff values for different commercial kits are used to determine the samples that would predicta true antibody response for Hepatitis C Virus infection. The aim of this study is to determine a specific signal/cutoffratio with the commercial kit that is used routinely in our laboratory that would predict a true antibody positive result95% of the time regardless of the anti-HCV prevalance.Material and Methods: A total number of 309 anti-HCV positive samples that were tested with the architect anti-HCVassay (Abbott Laboratories, IL, USA) were reviewed retrospectively and categorized according to their signal/cutoffratio. These samples were retested with LIA (Innogenetics N.V., Belgium). ROC-curve analysis in SPSS 17.0statistical package programme was used for data analysis.Results: The signal/cutoff ratio 3.27 is determined as the cutoff point that predicts a true antibody positive result in94.9% (positive predictive value 94.9 %, specificity 81.4%, sensitivity 91.2%) of the cases according to the ROCcurve analysis.Conclusion: A stepwise approach is appropriate for evaluation of patients positive for anti-HCV. It is important forlaboratories to determine a cutoff point to distinguish between a low and high positive Anti-HCV result. With thearchitect anti-HCV assay (Abbott, USA), in cases with signal/cutoff >3.27, the line immunoassay will be positive inmost patients, so supplementary testing in such individuals is not needed.

Özet

Amaç: Hepatit C virüs enfeksiyonunda farklı ticari kitler ile gerçek antikor pozitifliğini öngören farklı Anti-HCVsinyal/eşik değer oranları belirlenmiştir. Bu çalışmanın amacı, laboratuvarımızda rutin olarak kullanılan ticari kit içinanti-HCV prevalansından bağımsız olarak %95 gerçek antikor olumluluğunu öngören spesifik bir sinyal/eşik değeroranı belirlemektir.Gereç ve Yöntem: Architect anti-HCV (Abbott Laboratories, IL, ABD) kiti ile daha önce test edilen 309 anti-HCVpozitif örnek sinyal/eşik değerlerine göre sınıflandırıldı. Bu örnekler LIA (Innogenetics N.V., Belçika) ile tekrar testedildi. Veri analizi için 17.0 SPSS paket programındaki ROC eğri analizi kullanıldı.Bulgular: ROC eğrisi analizine göre 3.27 sinyal/eşik değer oranı, gerçek antikor pozitifliğini öngören eşik değerolarak bulundu (pozitif prediktif değer %94.9, özgüllük %81.4, duyarlılık %91.2).Sonuç: Anti-HCV pozitif bulunan hastaların değerlendirilmesinde basamaklı bir yaklaşım uygundur. Laboratuvarların,düşük ve yüksek anti-HCV pozitifliğini ayırt edebilecek bir eşik değer belirlemesi önemlidir. Architect anti-HCV testi(Abbott, ABD) ile sinyal/eşik değeri >3.27 olan örneklerde line immunoassay testi hastaların çoğunda pozitif olarakbulunacağından, bu hastalarda bu tip bir destekleme testinin uygulanmasına gerek yoktur.

🔖

Cite This Article

GÜRSEL, D., ALTUĞLU, İ., ORMAN, M., ERENSOY, S., AKSOY, A. (2022). The importance and role of anti-HCV signal/cutoff ratio in diagnosis of hepatitis C virus infection. Ege Tıp Dergisi, Cilt: 50 - Sayı: 4, 223–228. https://ajindex.com/articles/496186

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Chapko MK, Sloan KL, Davison JW, et al. Cost effectiveness of testing strategies for chronic hepatitis C. American J Gastroenterol 2005; 100: 607-615
  2. Richter SS. Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol 2002; 40: 4407- 4412
  3. Lok ASF, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997; 26: 48-56
  4. Carrithers RL, Maarquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis 2000; 28: 159–171
  5. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003; 7: 127-137
  6. Chevaliez S, Pawlowsky J. Hepatitis C virus: Virology, Diagnosis and mangement of antiviral therapy. World J Gastroenterol 2007;13: 2461-2466
  7. Dufour DR, Talastas M, Fernandez MDA, et al. Low positive anti-hepatitis C virus enzyme immunoassay results: An important predictor of low likelihood of hepatitis C infection. Clin Chemistry 2003; 49: 476-486
  8. Alter MJ, Kuhnert WL, Finelli L. Guidelines for Laboratory testing and result reporting of antibody to Hepatitis C virus. MMWR 2003; 52: 1-16
  9. National Institudes of Health. Management of Hepatitis C. NIH consensus statements 2002; 19; 1-44
  10. National Standard Method VSOP5i5. Investigation of hepatitis C infection. Issued August 10, 2005 by: Standards Unit, Evaluations and Standards Laboratory
  11. Perz JF, Farrington LA, Pecoraro C, et al. Estimated global prevalence of hepatitis C virus infection. 42nd Annual Meeting of the Infectious Diseases Society of America; Boston, MA, USA; September 30-October 3, 2004
  12. Barreto AMCE, Takei K, Sabino EC, Bellesa MAO, et al. Cost-effective analysis of different algorithms for the diagnosis of hepatitis C virus infection 2008; 41: 126-134
  13. Oethinger M, Mayo DR, Falcone J, et al. Efficiency of the Ortho VITROS assay for detection of hepatitis C virus specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios. J Clin Microbiol 2005; 43: 2477-2480
  14. Echevarria JM, Avellon A, Jonas G, et al. Sensitivity of a modified version of the ARCHITECT Anti-HCV test in detecting samples with immunoblot-confirmed, low-level antibody to hepatitis C virus. J Clin Virol 2006; 35: 368-372 15. Jonas G, Pelzer C, Beckert C, et al. Performance characteristics of the ARCHITECT Anti-HCV assay. J Clin Virol 2005; 34: 97-103
  15. Kim S, Kim JH, Yoon S, et al. Clinical performance evaluation of four automated chemiluminescence immun